Company Description
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes.
In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 142 |
| CEO | Gavin MacBeath |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 857 399 9500 |
| Website | tscan.com |
Stock Details
| Ticker Symbol | TCRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1783328 |
| CUSIP Number | 89854M101 |
| ISIN Number | US89854M1018 |
| Employer ID | 82-5282075 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gavin MacBeath Ph.D. | Chief Executive Officer and Director |
| Jason A. Amello CPA | Chief Financial Officer, Treasurer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Chrystal U. Louis M.D., M.P.H. | Chief Medical Officer |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Tomasz Kula Ph.D. | Co-Founder and Member of Advisory Board |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal and Strategy Officer and Company Secretary |
| Ann Hargraves | Chief Human Resources Officer |
| Dr. Shrikanta Chattopadhyay M.D. | Senior Vice President and Head of Translational Medicine |
| Ray Lockard M.B.A. | Chief Manufacturing and Quality Officer |
| Jim Murray | Chief Development Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | 8-K | Current Report |
| Apr 17, 2026 | ARS | Filing |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 4, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |